Year: 2024

Ontario, Toronto, December 12, 2024 – The leading expert in 3D-driven enterprise software as a service Virtualware (EPA: MLVIR) partners with Invest WindsorEssex (IWE) and NextStar Energy in the innovative Battery Boost: Technical Training for Battery Manufacturing Careers program. Supported by over $3.8 million in funding from Upskill Canada and powered by Palette Skills with the backing of the Government of Canada, this regional program equips workers with practical and advanced skills essential for the growing battery manufacturing sector. The Battery Boost program offers innovative technical training to prepare individuals for careers in battery manufacturing, focusing on laid-off workers or those seeking a career change. Using Virtual Reality (VR) and advanced simulators, participants gain practical, hands-on experience for immediate...

In November, EfTEN Real Estate Fund AS earned consolidated rental income of EUR 2,602 thousand, which is EUR 32 thousand more than in October. The increase in rental income is mainly attributable to the first full-month rental income from a new investment – the Härgmäe logistics center. Additionally, rental income increased due to a decreased vacancy at the Evolution office building in Vilnius. The vacancy rate of the fund’s investment portfolio fell to 3.0% in November (compared to 3.2% in October). The fund’s consolidated EBITDA in November amounted to EUR 2,198 thousand, which is EUR 43 thousand higher than in the previous month. This increase is due to stable general administrative expenses and lower marketing campaign costs in shopping centers. The weighted average interest rate on the bank loans of the fund and its subsidiaries...

Quobly Forges Strategic Collaboration with STMicroelectronicsto Accelerate its Quantum Processor Manufacturing for Large-Scale Quantum Computing SolutionsCollaboration will leverage ST’s 28nm FD-SOI commercial semiconductor volume manufacturing processes to pave the way towards cost-competitive, large-scale quantum computing solutions.Quobly and ST envision the first generation of commercial products to be available by 2027, targeting applicative markets including materials development and systems modeling.Grenoble, France and Geneva, Switzerland – December 12, 2024 – Quobly, a cutting-edge quantum computing startup, today announced a transformative collaboration with STMicroelectronics, a global semiconductor leader serving customers across the spectrum of electronics applications, to produce quantum processor units (QPUs) at scale....

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants will have an exercise price of $0.9375 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts...

SAN JOSE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — Nutanix, Inc. (“Nutanix”) (Nasdaq: NTNX) , a leader in hybrid multicloud computing, today announced the pricing of $750 million aggregate principal amount of 0.50% convertible senior notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Nutanix has granted the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The sale of the notes to the initial purchasers is expected to settle on December 16, 2024, subject to satisfaction of customary closing conditions. The...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This treatment combination is being evaluated in China in the ongoing multi-center,...

RENO, Nev., Dec. 11, 2024 (GLOBE NEWSWIRE) — Ormat Technologies, Inc. (NYSE: ORA) (“Ormat” or the “Company”), a leading geothermal and renewable energy technology company, announced today the pricing of an underwritten secondary offering of 3,700,000 shares of its common stock on behalf of ORIX Corporation. The offering is expected to close on December 13, 2024, subject to customary closing conditions. Ormat is not offering any of its common stock in the offering for its own account and will not receive any proceeds from the sale of the shares being offered by the selling stockholder. Goldman Sachs & Co. LLC is acting as the sole book-running manager and underwriter for the offering. The shares of common stock are being sold to the public at an initial price of $76.20 per share. Goldman Sachs & Co. LLC will have a 30-day...

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999...

HAUPPAUGE, N.Y., Dec. 11, 2024 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced that it has entered into one or more securities purchase agreements with certain institutional investors to purchase 1,352,500 shares of common stock (the “Securities”) at an offering price of $1.60 per share, in a registered direct offering. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.2 million before deducting the placement agent’s fees and other estimated...